EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA

This study tests whether using specific features of a person's lung cancer (biomarkers) can help doctors choose the best maintenance treatment to keep the cancer from growing. About 900 people with extensive-stage small cell lung cancer will receive standard initial therapy, then…

This study tests a drug called tarlatamab in people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. Tarlatamab works by helping the body's immune cells attack cancer cells. The goal is to see if it can slow the cancer's growth and help patients…

This study tests a combination of chemotherapy (temozolomide) and immunotherapy (atezolizumab) for people with small cell lung cancer that has spread or returned after initial treatment. The goal is to see if this combo can shrink tumors and help patients live longer. About 56 ad…

This study tests whether adding lamivudine, an antiviral drug, to standard chemotherapy and immunotherapy can stop small cell lung cancer from becoming resistant to treatment. About 28 adults with extensive-stage small cell lung cancer will receive the combination. The goal is to…

This study is for people with extensive-stage small cell lung cancer that has responded to initial chemotherapy plus immunotherapy. It compares standard maintenance immunotherapy alone versus adding radiation therapy to see if the combination delays cancer growth or spread. About…

This study tests whether adding the drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can keep extensive-stage small cell lung cancer from growing longer than immunotherapy alone. About 45 adults whose cancer responded to initial chemo-immunotherapy will par…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve cancer symptoms without causing too many side effects. …